Kiniksa Pharmaceuticals Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kiniksa Pharmaceuticals Corporation
GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.
Zydus has established proof of concept for ZYIL1, a NLRP3 inflammasome inhibitor to treat cryopyrin-associated periodic syndromes, via Phase II trials in Australia. Will the oral drug have an upper hand over injectables like Novartis’ Ilaris?
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.
Keeping Track: Pediatric Approvals, Seres Starts C Diff Submission, And BMS Pulls Reblozyl sBLA Before Possible CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Specialty Pharmaceuticals
- Large Molecule
- Other Names / Subsidiaries
- Kiniksa Pharmaceuticals, Ltd.
- Kiniksa Pharmaceuticals Corp.
- Primatope Therapeutics, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.